GlaxoSmithKline's CEO on the China Controversy, Transparency, and Big Pharma's Reputation | Forbes

3,380 views · Published 18 October 2013 · 6:47 · Indexed 8 November 2026

Channel: Forbes · 2013 · Science & Technology

Watch on YouTube

Forbes Senior Editor Matthew Herper sits down with Sir Andrew Witty to ask how accusations of bribery have affected the company's reputation, its efforts at releasing clinical trial data, and its malaria vaccine.

More from this channel